Clover Health Investments Corp - Ordinary Shares - Class A Aktie News

WILMINGTON, Del., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Thursday, February 26, 2026.

Clover Health Investments is now a contrarian buy, with the market underestimating its path to profitability in 2026. CLOV's member retention exceeds 90%, older cohorts generate $217 monthly profit, and the Clover Assistant AI is driving clinical and financial improvements. The stock trades at less than 0.5x 2026 sales, with a fair value estimate of $3.30 per share—28% above current levels.

Clover Health Investments, Corp. (CLOV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Clover delivers market-leading Medicare Advantage growth, establishing a strong path to achieve its first-ever full year GAAP Net Income profitability in 2026. Disciplined, core-market growth, strong returning member retention, and improving cohort economics position Clover for compounding earnings and margin expansion.

SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Counterpart Health , Inc. (“Counterpart” or the “Company”), a leading AI-powered physician-enablement platform and subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV), today released key 2025 highlights. The past year was defined by continued publication of research demonstrating the platform's impact on chronic disease management, mean...

WILMINGTON, Del., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Executive Officer, Andrew Toy, will present at the J.P.

Clover Health Investments, Corp. (CLOV) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Despite disappointing YTD earnings due to higher than expected medical costs, Clover's expected GAAP profitability in 2026 marks a critical inflection point. Clover's higher returning member mix and targeted growth measures aiming to bring more members under Clover Assistant quicker are major tailwinds to medical costs next year, in my opinion. Clover Assistant's early diagnosis capabilities se...